Search

Objective: Amygdalin (Vitamin B-17) is a type of vitamin, naturally found in many fruits and plants. The aim of the study was the evaluation of Amygdalin effect on the oxidant capacity and oxidant status of the T98G cancer cells. A T98G cell line was used in the study. Cell viability and oxidative stress evaluation were done. Methods: Amygdalin was used at 1, 4, and 8 µg/mL doses. TAC and TOS values were measured. Results: According to the result, amygdalin 8 µg/mL shows the highest anticancer effects. TAC level was 3.2 Trolox Equiv/L and TOS was 3.6 H2O2 Equiv/L. Conclusion: Vit B17 can increase oxidative stress in T98G cells and decrease cell viability

Amaç: Prostat kanseri (PC), dünya çapında erkeklerde kanserden ölümlerin en yaygın nedenlerinden biridir ve PC'yi tedavi etmek için yeni ilaçlar halen geliştirilmektedir. Şırınga asidi (SA), çeşitli tümörlerde antiinflamatuar ve metabolik düzenleyici etkiler ve antitümör aktiviteleri sergileyen bir polifenolik bileşiktir. Bu çalışma, SA'nın DU-145 hücreleri üzerindeki antiproliferatif ve antitümör aktivitelerini araştırmayı amaçladı. Yöntemler: SA'nın antiproliferatif etkisini belirlemek için MTT, antioksidan-oksidan etkilerini belirlemek için SOD-MDA analizleri kullanıldı. Bulgular: SA, in vitro olarak DU-145 hücre proliferasyonunu önemli ölçüde baskıladı. Ayrıca SOD düzeylerini düşürürken, MDA düzeylerinde ise ciddi bir artışa neden olmuştur. Sonuç: Bulgularımız SA'nın iyileştirici etkisini hedef alarak PC'nin antitümör potansiyelini ortaya çıkardı.Anahtar Kelimeler: DU-145, MDA, Prostat kanseri, SOD, Şırınga asidi

INTRODUCTION: This study aimed to explain the beneficial effects and possible protective mechanisms of Sinapic acid(SA) against cisplatin-induced oxido-inflammatory damage in HT-22 rat hippocampal cells by biochemical and molecular methods. METHODS: Primarily, different concentrations of SA (100, 400 and 800 µM) were applied to HT-22 cells under in vitro conditions before cisplatin application in order to produce neuroprotective activity. Half an hour after the SA application, 5.5 µM cisplatin (CP) was applied to all wells except the control group and incubated for 24 hours under appropriate conditions. Cell viability was determined with routinely used 3-(4,5-Dimethyl Thiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) and cytotoxic activity was determined by lactate dehydrogenase (LDH) assays. Oxidative stress was evaluated by total antioxidant capacity (TAC), catalase (CAT), glutathione (GSH), malondialdehyde (MDA) and superoxide dismutase (SOD) assays. In addition, the effect of SA on Caspase-3 gene regulation in HT-22 cells was investigated by Real-Time PCR. RESULTS: Cisplatin decreased cell viability by approximately 40% and increased LDH level in HT-22 cells. In SA administered groups, cell viability increased and LDH level decreased regardless of dose. SA showed its neuroprotective effect by stopping the cytotoxic activity of cisplatin and increasing its antioxidant action mechanism in cells. Similarly, caspase-3 up-regulated by cisplatin approached the control value with SA administration. SA abolished the neurotoxicity of cisplatin and significantly reduced cell death and oxidative stress levels (p

Aim: The aim of our study is to the evaluation of melatonin (MLT) and Momordica charantia (MC) combination on PC-3 and HT-29 cancer lines and to address the question of where or not MLT increases MC antitumor effect in the PC-3 and HT-29 cancer lines. Material and Method: The PC-3 and HT-29 cell lines were grown in a manufacturer-specified culture medium. Cisplatin, MLT, increasing concentrations of MC, 40 μg/ml MLT + increasing concentrations MC were applied to PC-3 and HT-29 cell lines for 72 hours. 3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide (MTT) cell viability, Total Antioxidant Capacity (TAC), Total Oxidant Status (TOS), Cellular Migration (Wound Healing test), and Lactate Dehydrogenase (LDH) tests were done 72 hours after drug administration. Results: The combination of MLT 40 μg/ml + MC 100 µg/ml reduced cell viability in both PC-3 and HT-29 cells. Besides, TAC and TOS levels showed a correlation with LDH and MTT assays and were found to be statistically significant (P

Abstract Parkinson’s disease (PD) is a chronic neurodegenerative case. As the disease progresses, the response time to doses of levodopa (L-Dopa) becomes shorter and the effects of the drug are severely limited by some undesirable side effects such as the ‘on–off’ phenomenon. In several diseases, including Parkinson’s, nanoparticles can deliver antioxidant compounds that reduce oxidative stress. This study evaluates and compares the neuroprotective effects of L-Dopa-modified zinc nanoparticles (ZnNPs) in the 6-hydroxydopamine (6-OHDA)-induced PD rat model. For this purpose, the synthesis of NPs was carried out. Scanning electron microscopy, X-ray diffraction and Fourier transform infrared spectrophotometer were used for characterization. The rats were randomized into 9 experimental groups: control, lesion group (6-OHDA), 6-OHDA + 5 mg/kg L-Dopa, 6-OHDA + 10 mg/kg L-Dopa, 6-OHDA + 20 mg/kg L-Dopa, 6-OHDA + 20 mg/kg ZnNPs, 6-OHDA + 40 mg/kg ZnNPs, 6-OHDA + 30 mg/kg ZnNPs + L-Dopa, and 6-OHDA + 60 mg/kg ZnNPs + L-Dopa. Behavioral tests were performed on all groups 14 days after treatment. Phosphatase and tensin homolog, Excitatory amino acid transporter 1/2, and Glutamine synthetase gene analyses were performed on brain samples taken immediately after the tests. In addition, histological and immunohistochemical methods were used to determine the general structure and properties of the tissues. We obtained important findings that L-Dopa-modified ZnNPs increased the activity of glutamate transporters. Our experiment showed that glutamate increases neuronal cell vitality and improves behavioral performance. Therefore, L-Dopa-modified ZnNPs can be used to prevent neurotoxicity. According to what we found, results show that L-Dopa-modified ZnNPs will lend to the effective avoidance and therapy of PD.

According to population-based studies, lung cancer is the prominent reason for cancer-related mortality worldwide in males and is also rising in females at an alarming rate. Sorafenib (SOR), which is approved for the treatment of hepatocellular carcinoma and renal cell carcinoma, is a multitargeted protein kinase inhibitor. Additionally, SOR is the subject of interest for preclinical and clinical trials in lung cancer. This study was designed to assess in vivo the possible effects of sorafenib (SOR) in diethylnitrosamine (DEN)-induced lung carcinogenesis and examine its probable mechanisms of action. A total of 30 adult male rats were divided into three groups (1) control, (2) DEN, and (3) DEN + SOR. The chemical induction of lung carcinogenesis was performed by injection of DEN intraperitoneally at 150 mg/kg once a week for two weeks. The DEN-administered rats were co-treated with SOR of 10 mg/kg by oral gavage for 42 alternate days. Serum and lung tissue samples were analyzed to determine SRY-box transcription factor 2 (SOX-2) levels. The tumor necrosis factor alpha (TNF-α) and interleukin-1 beta (IL-1β) levels were measured in lung tissue supernatants. Lung sections were analyzed for cyclooxygenase-2 (COX-2) and c-Jun N-terminal kinase (JNK) histopathologically. In addition, cyclooxygenase-2 (COX-2) and c-Jun N-terminal kinase (JNK) were analyzed by immunohistochemistry and immunofluorescence methods, respectively. SOR reduced the level of SOX-2 that maintenance of cancer stemness and tumorigenicity, and TNF-α and IL-1β levels. Histopathological analysis demonstrated widespread inflammatory cell infiltration, disorganized alveolar structure, hyperemia in the vessels, and thickened alveolar walls in DEN-induced rats. The damage was markedly reduced upon SOR treatment. Further, immunohistochemical and immunofluorescence analysis also revealed increased expression of COX-2 and JNK expression in DEN-intoxicated rats. However, SOR treatment alleviated the expression of these inflammatory markers in DEN-induced lung carcinogenesis. These findings suggested that SOR inhibits DEN-induced lung precancerous lesions through decreased inflammation with concomitant in reduced SOX-2 levels, which enables the maintenance of cancer stem cell properties.

(1) Background: Colon cancer is one of the most common cancer types, and treatment options, unfortunately, do not continually improve the survival rate of patients. With the unprecedented development of nanotechnologies, nanomedicine has become a significant direction in cancer research. Indeed, chemotherapeutics with nanoparticles (NPs) in cancer treatment is an outstanding new treatment principle. (2) Methods: Fe3O4 NPs were synthesized and characterized. Caco-2 colon cancer cells were treated during two different periods (24 and 72 h) with Fe3O4 NPs (6 μg/mL), various concentrations of 5-FU (4–16 μg/mL), and Fe3O4 NPs in combination with 5-FU (4–16 μg/mL) (Fe3O4 NPs + 5-FU). (3) Results: The MTT assay showed that treating the cells with Fe3O4 NPs + 5-FU at 16 µg/mL for 24 or 72 h decreased cell viability and increased their LDH release (p < 0.05 and p < 0.01, respectively). Furthermore, at the same treatment concentrations, total antioxidant capacity (TAC) was decreased (p < 0.05 and p < 0.01, respectively), and total oxidant status (TOS) increased (p < 0.05 and p < 0.01, respectively). Moreover, after treatment with Fe3O4-NPs + 5-FU, the IL-10 gene was downregulated and PTEN gene expression was upregulated (p < 0.05 and p < 0.01, respectively) compared with those of the control. (4) Conclusions: Fe3O4 NPs exert a synergistic cytotoxic effect with 5-FU on Caco-2 cells at concentrations below the active drug threshold levels.

High-grade gliomas are the most fatal brain tumors. Grade 4 gliomas are called glioblastoma multiforme (GBM), which are associated with the poorest survival and a 5-year survival rate of less than 4%. Many patients with GBM developed concomitant cognitive dysfunctions and epilepsy. Although the cognitive decline is well defined in glioblastomas, the neurotoxic factors underlying this pathology are not well understood in GBM patients. In this study, we aimed to investigate whether GBM-derived exosomes play a role in neuronal toxicity. For this purpose, exosomes obtained from T98G and U373 GBM cells were applied to primary neuron culture at different concentrations. Subsequently, MTT, LDH, GSH, TAS, and TOS tests were performed. Both GBM-derived exosomes induced a dose-dependent and statistically significant increase of LDH release in cerebellar neurons. MTT assay revealed as both T98G and U373 GBM-derived exosomes induced dose-dependent neurotoxic effects in cerebellar neurons. To the best of our knowledge, this study is the first study demonstrating the toxic potential of GBM-derived exosomes to primary neurons, which may explain the peritumoral edema and cognitive decline in GBM patients.